Sugi Predict

Sugi Predict / Compounds / SCHEMBL12834802

SCHEMBL12834802

SCHEMBL12834802

CCc1ccc(CC)c(C(F)(F)F)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FFAR4 Q5NUL3 1/20 0.40
▸ TRPA1 O75762 1/20 0.39
▸ IDO1 P14902 4/20 0.38
▸ RXRA P19793 2/20 0.38
▸ RXRB P28702 2/20 0.38
▸ RXRG P48443 2/20 0.38
▸ CYP1A2 P05177 2/20 0.38
▸ CYP2A6 P11509 1/20 0.38
▸ NPC1 O15118 2/20 0.37
▸ RAB9A P51151 2/20 0.37
▸ SMN1; SMN2 Q16637 2/20 0.37
▸ ALDH1A1 P00352 1/20 0.37
▸ LMNA P02545 1/20 0.37
▸ MAPT P10636 1/20 0.37
▸ MAPK1 P28482 1/20 0.37
▸ L3MBTL1 Q9Y468 1/20 0.37
▸ PDK2 Q15119 1/20 0.37
▸ EPHX2 P34913 1/20 0.36
▸ PPARG P37231 1/20 0.36
▸ CYP2C19 P33261 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3902001 0.86 IDO1 (0.38) FFAR4IDO1RXRARXRBRXRG
SCHEMBL3903466 0.86 KIF11 (0.45) IDO1RXRARXRBRXRGPDK2
SCHEMBL12114208 0.86 S1PR1 (0.37) FFAR4TRPA1IDO1RXRARXRB
SCHEMBL18570760 0.86 HSPA5 (0.38) FFAR4TRPA1CYP1A2CYP2A6NPC1
SCHEMBL14273254 0.84 RXRA (0.50) RXRARXRBRXRG
SCHEMBL24823198 0.83 GABRA1 (0.43) LMNAMAPTEPHX2PPARGHTR2A
SCHEMBL26145454 0.83 FFAR4 (0.40) FFAR4TRPA1RXRARXRBRXRG
SCHEMBL3245823 0.83 RXRA (0.44) FFAR4TRPA1IDO1RXRARXRB
SCHEMBL19789643 0.82 PDE3B (0.47) FFAR4TRPA1IDO1CYP1A2CYP2A6
SCHEMBL27408304 0.82 TP53 (0.42) CYP1A2CYP2A6ALDH1A1PDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022268066-A1 PROTEIN DEGRADATION AGENT 苏州开拓药业股份有限公司 2022-12-29 — — WO disclosed
CN-106928091-B Fluorochemical and its synthetic method 南开大学 2018-12-04 — — CN disclosed
US-20110053892-A1 Imidazo[4,5-d]Pyridazine Compounds For Treating Viral Infections LEIVERS MARTIN 2011-03-03 — — US disclosed
US-20110052534-A1 Imidazopyridazine Compounds for Treating Viral Infections LEIVERS MARTIN 2011-03-03 — — US disclosed
WO-2008030448-A1 PHENETHYLAMIDE DERIVATIVES WITH KINASE INHIBITORY ACTIVITY MILLENNIUM PHARMACEUTICALS, INC. (US) 2008-03-13 — — WO disclosed
WO-2007067444-A1 BICYCLIC COMPOUNDS WITH KINASE INHIBITORY ACTIVITY MILLENNIUM PHARMACEUTICALS, INC. (US) 2007-06-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110052534-A1 Imidazopyridazine Compounds for Treating Viral Infections ACE, ACE2, TPMT FFAR4 3690/4885TRPA1 1213/4885IDO1 273/4885
US-20110053892-A1 Imidazo[4,5-d]Pyridazine Compounds For Treating Viral Infections MAVS, ZC3HAV1, IL5 FFAR4 2842/4885TRPA1 1481/4885IDO1 140/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.